[NASDAQ:IDRA] IDERA PHARMACEUTICALS, INC. > 11.84
Idera Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of synthetic DNA and RNA-based compounds for the treatment of cancer, infectious diseases, autoimmune diseases, asthma/allergies, and for use as vaccine adjuvants. It designs proprietary product candidates that are designed to modulate immune responses through Toll-like Receptors, the body's first line of immune defense. The company's DNA chemistry enables it to identify product candidates for the internal development programs and creates opportunities for multiple collaborative alliances. Its drug candidates include IMO-2055, an agonist of TLR9, which is in Phase II trial for renal cell carcinoma; and IMO-2125, a lead product candidate for treating infectious diseases. The company is collaborating with Merck & Co., Inc. to research, develop, and commercialize vaccine products containing its TLR7, 8, or 9 agonists in the fields of oncology, infectious diseases, and Alzheimer's disease. It is also collaborating with Novartis International Pharmaceutical, Ltd. to discover, develop, and commercialize TLR9 agonists for the treatment of asthma and allergies.
 |
